#	Pagina
attuale pagina	/open-h2020/projects/211976/index.html
-1	/open-h2020/per-country/th/chulalongkorn+university/index.html

Opendata, web and dolomites

ANTHEM SIGNED

ANTHEM: A Novel Tolerogenic vaccine for the treatment of antibodies in HaEMophilia

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ANTHEM project word cloud

Explore the words cloud of the ANTHEM project. It provides you a very rough idea of what is the project "ANTHEM" about.

safety iti strategy 3012 reprogrammed strategic serious pressing million validate policy lifetime viii cells idogen crippling lies therapy mean cornerstone heavy date burden patient morbidities arthropathy na 117 resistance patients prevalence exerts haemophilia basis establishing transferred outside antibodies person commercialisation reactions supports health safe clotting care uses neutralizing capacity humans eradicate data eur mechanism counteract efficacy 35 budgets emphasise platform clinical leads induction utilizes consequence trial vulnerable situation annual reaching haematologists protein failed tolerogenic preliminary back vaccine tolerance overcome body treatment kols constitute adverse healthcare substantially realize dendritic technologies blood immune mortality create treat accelerated performed standard

Project "ANTHEM" data sheet

The following table provides information about the project.

Coordinator	IDOGEN AB Organization address address: SCHEELEVAGEN 2 city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://idogen.com
Total cost	2˙868˙734 €
EC max contribution	2˙868˙734 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-09-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	IDOGEN AB IDOGEN AB Organization address address: SCHEELEVAGEN 2 city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	coordinator	2˙868˙734.00

Map

Project objective

This project will develop and validate IN-3012, a novel tolerogenic vaccine that utilizes a person’s own cells to treat neutralizing antibodies (NA) in Haemophilia A patients who have failed immune tolerance induction (ITI). Haemophilia A patients are given the blood clotting protein, factor VIII as standard of care. However, a serious consequence is the development of NA towards factor VIII leading to therapy resistance. This leads to crippling arthropathy, other morbidities and high mortality. ITI is the most used treatment of this condition but 35% of patients do not respond and are in a vulnerable situation.

Haematologists and KOLs emphasise the pressing need for safe and effective technologies to overcome NA in Haemophilia A, which is not possible today. The estimated mean annual cost of a Haemophilia patient in Europe is over EUR 117,000 EUR with the mean lifetime cost reaching EUR 7.8 million. This is substantially higher in patients who have failed ITI. Therefore, while this condition has low prevalence, it exerts heavy burden on healthcare budgets and is thus a top EU health policy priority.

Idogen’s technology platform allows cells from the patient’s blood to be reprogrammed outside the body to dendritic cells with the capacity to specifically counteract adverse immune reactions. The reprogrammed cells are transferred back to the patient. IN-3012 uses this mechanism to create tolerance to factor VIII.

The research performed to date strongly supports the vaccine’s potential to eradicate NA. The proposed project will bring IN-3012 through a Phase I/II clinical trial in humans. The safety and preliminary efficacy data will constitute the basis for further clinical development and commercialisation of the product. Idogen’s strategic focus lies in establishing IN-3012 as a novel treatment in Haemophilia A patients having failed ITI. This will constitute the cornerstone of Idogen’s accelerated growth. This project is the key step to realize the strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTHEM" are provided by the European Opendata Portal: CORDIS opendata.